Evidence for Oncolytic Virotherapy: Where Have We Got to and Where Are We Going?

Evidence for Oncolytic Virotherapy: Where Have We Got to and Where Are We Going?

The last few years have seen an increased interest in immunotherapy in the treatment of malignant disease. In particular, there has been significant enthusiasm for oncolytic virotherapy, with a large amount of pre-clinical data showing promise in animal models in a wide range of tumour types. How do...

Full description

Bibliographic Details
Main Authors: Samantha Turnbull, Emma J. West, Karen J. Scott, Elizabeth Appleton, Alan Melcher, Christy Ralph
Format: Article
Language:English
Published: MDPI AG 2015-12-01
Series:Viruses
Subjects:
oncolytic virus
immunotherapy
reovirus
vaccinia
HSV
clinical trials
Online Access:http://www.mdpi.com/1999-4915/7/12/2938
Description
Summary:The last few years have seen an increased interest in immunotherapy in the treatment of malignant disease. In particular, there has been significant enthusiasm for oncolytic virotherapy, with a large amount of pre-clinical data showing promise in animal models in a wide range of tumour types. How do we move forward into the clinical setting and translate something which has such potential into meaningful clinical outcomes? Here, we review how the field of oncolytic virotherapy has developed thus far and what the future may hold.
ISSN:1999-4915

Similar Items